ASX:EMDPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals

EMYRIA ORD

$0.056
Day Range
$0.055 - $0.057
52 Week Range
$0.021 - $0.078
Volume
927.73K
Avg Volume (10D)
1.27M
Market Cap
$45.17M
Price Chart
Market Statistics
Open$0.057
Previous Close$0.056
Day High$0.057
Day Low$0.055
52 Week High$0.078
52 Week Low$0.021
Valuation
Market Cap45.17M
Shares Outstanding806.56M
Price to Book6.34
Trading Activity
Volume927.73K
Value Traded51.38K
Bid$0.055 × 166,138
Ask$0.056 × 285,015
Performance
1 Day-5.17%
5 Day0.00%
13 Week-16.67%
52 Week57.14%
YTD-6.78%
Technical Indicators
RSI (14)49.12
50-Day SMA$0.056
200-Day SMA$0.048
Latest News
Emyria Introduces First Empax Centre to Victoria with Expanded Medibank Funding Agreement
Biotechnology

Emyria Introduces First Empax Centre to Victoria with Expanded Medibank Funding Agreement

Emyria expands Medibank funding to Victoria, unlocking Empax TRD/PTSD care at Avive Mornington Peninsula; nationwide rollout underway.

1 min read
Imelda Cotton
Imelda Cotton
Emyria Establishes First Victorian Empax Clinic for Psychedelic-Assisted Treatments
Biotechnology

Emyria Establishes First Victorian Empax Clinic for Psychedelic-Assisted Treatments

Perth-based mental health care specialist Emyria (ASX: EMD) has secured its first Empax clinic in Victoria for the psychedelic-assisted treatment of post-traumatic stress disorder (PTSD) and treatment-resistant depression.

1 min read
Imelda Cotton
Imelda Cotton
Emyria Commences Empax PTSD Care Program at Perth Clinic and Launches Interstate Expansion
Biotechnology

Emyria Commences Empax PTSD Care Program at Perth Clinic and Launches Interstate Expansion

Emyria (ASX: EMD) has begun delivering its Empax therapy for post-traumatic stress disorder (PTSD) at a Perth clinic under Australia’s first private health insurance program for psychedelic-assisted treatment. Medibank Private (ASX: MPL) is funding the program under an initial two-year agreement secured in June and will make it available to eligible health fund members. The […]

1 min read
Imelda Cotton
Imelda Cotton
Emyria’s Empax PTSD trauma care program gains funding support from Medibank Private
Biotechnology

Emyria’s Empax PTSD trauma care program gains funding support from Medibank Private

Health insurer Medibank Private (ASX: MPL) has commenced funding for eligible members to access the Empax post-traumatic stress disorder (PTSD) care program developed by Emyria (ASX: EMD) and Perth Clinic. The initial two-year agreement marks the first major private health insurance funding of a psychotherapy-led PTSD program in Australia and Emyria regards the move as […]

2 min read
Imelda Cotton
Imelda Cotton